Schechter, Michael S. http://orcid.org/0000-0002-8473-3767
Sabater-Anaya, Natalia
Oster, Gerry
Weycker, Derek
Wu, Hongsheng
Arteaga-Solis, Emilio
Bagal, Sukirti
McGarry, Lisa J.
Van Brunt, Kate
Geiger, Jessica Morlando
Funding for this research was provided by:
Vertex Pharmaceuticals Incorporated
Article History
Received: 12 June 2023
Accepted: 14 September 2023
First Online: 24 October 2023
Declarations
:
: All authors received nonfinancial support (assistance with manuscript preparation) from ArticulateScience LLC, which was funded by Vertex Pharmaceuticals. Additional disclosures are as follows: Michael S. Schechter reports consulting fees and grants to his institution from Vertex Pharmaceuticals; grants to his institution from GSK, the US Cystic Fibrosis Foundation, and National Institutes of Health; speaker fees from Sanofi; participation on an advisory or safety monitoring board for AstraZeneca; payments for participation on US Cystic Fibrosis Foundation committees; unpaid participation on the US Cystic Fibrosis Foundation Virginia Chapter Board of Directors; and personal payments for expert testimony in malpractice litigation. Natalia Sabater-Anaya, Gerry Oster, Derek Weycker, and Hongsheng Wu are employees of Policy Analysis Inc., which received research funding from Vertex Pharmaceuticals. Emilio Arteaga-Solis, Lisa J. McGarry, Kate Van Brunt, and Jessica Morlando Geiger are employees of Vertex Pharmaceuticals and may own stock or stock options in that company. Sukirti Bagal was a former employee of Vertex Pharmaceuticals and is now an employee of Celldex Therapeutics and may own stock or stock options in that company.
: This study was conducted in accordance with the Declaration of Helsinki, the International Society for Pharmacoepidemiology Guidelines for Good Pharmacoepidemiology Practices, and the International Society for Pharmacoeconomics and Outcomes Research Good Practices for Outcomes Research. The study protocol was reviewed and determined exempt from ethical review requirements by an institutional review board because it was limited to the analysis of deidentified data from the Merative MarketScan® Commercial Claims and Encounters Database and the Merative Multi-State Medicaid Database.